Richard A. Larson to Receptors, Vascular Endothelial Growth Factor
This is a "connection" page, showing publications Richard A. Larson has written about Receptors, Vascular Endothelial Growth Factor.
Connection Strength
0.057
-
Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance). Br J Clin Pharmacol. 2014 Nov; 78(5):1005-13.
Score: 0.030
-
A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Invest New Drugs. 2013 Oct; 31(5):1311-20.
Score: 0.027